Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance

Clin Infect Dis. 2000 Jan;30(1):71-7. doi: 10.1086/313606.

Abstract

Limited data are available on clinical outcomes of meningitis due to cefotaxime-nonsusceptible Streptococcus pneumoniae. We analyzed data from 109 cases of pneumococcal meningitis in Atlanta, Baltimore, and San Antonio, which were identified through population-based active surveillance from November 1994 to April 1996. Pneumococcal isolates from 9% of the cases were resistant to cefotaxime, and isolates from 11% had intermediate susceptibility. Children were more likely to have cephalosporin-nonsusceptible pneumococcal meningitis, but mortality was significantly higher among adults aged 18-64 years. Vancomycin was given upon admission to 29% of patients, and within 48 h of admission to 52%. Nonsusceptibility to cefotaxime was not associated with the following outcomes: increased mortality, prolonged length of hospital or intensive care unit (ICU) stay, requirement of intubation or oxygen, ICU care, discharge to another medical or long-term-care facility, or neurological deficit. Empirical use of vancomycin, current prevalence of drug-resistant S. pneumoniae, and degree of nonsusceptibility to cefotaxime may have influenced these findings.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Distribution
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Cefotaxime / pharmacology*
  • Cephalosporin Resistance*
  • Cephalosporins / pharmacology*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Meningitis, Pneumococcal / drug therapy
  • Meningitis, Pneumococcal / epidemiology
  • Meningitis, Pneumococcal / microbiology*
  • Meningitis, Pneumococcal / pathology
  • Middle Aged
  • Population Surveillance
  • Risk Factors
  • Streptococcus pneumoniae / drug effects*
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Vancomycin
  • Cefotaxime